Head to head
Hims vs Henry Meds
These two are not the same purchase. Henry Meds supplies compounded medication; Hims supplies FDA-approved drugs only. Everything below is from the record, and every regulatory action links to its document.
- Hims
- FDA-approved
$149/mo - Henry Meds
- Compounded
$179/mo - Hims on file
- 4
- Henry Meds on file
- 1
Side by side
What each one publishes about itself
Every figure here is the provider’s own advertised number, not an estimate. A dash means the company does not publish it.
| Hims | Henry Meds | |
|---|---|---|
| Supplies | FDA-approved medication only | Compounded only |
| Advertised from | $149/mo | $179/mo |
| First month | $39 | — |
| Medication in the price | Billed separately | Included |
| Insurance | Cash pay | Cash pay |
| Intake | Async | Async |
| On the record | 4 actions | 1 action |
The difference that actually matters
Henry Meds supplies compounded semaglutide or tirzepatide — medication prepared by a compounding pharmacy, not an FDA-approved product. Cheaper, legal, and the category the FDA has been issuing warning letters about.
Hims supplies the approved drugs and nothing else, which puts it outside the compounding enforcement entirely — and is a large part of why it costs what it costs.
What is on Hims’s record
2025-09
FDA warning letter to Hims & Hers Health, Inc. dba Hims (MARCS-CMS 716567) over compounded GLP-1 marketing.
2026-03
Novo Nordisk sued Hims & Hers for infringement of US Patent 8,129,343 in the District of Delaware on 9 February 2026 (No. 1:26-cv-00143) and voluntarily dismissed it without prejudice on 9 March 2026, expressly reserving the right to refile, under an agreement in which Hims & Hers stopped advertising compounded GLP-1s and began distributing Novo's FDA-approved semaglutide.
2026-07
The FTC, the State of Utah and Los Angeles County sued Hims & Hers Health, Inc. in the Northern District of California under FTC Act section 5 and ROSCA, alleging the company disclosed customers' health information to advertising platforms including Meta and Snap, charged consumers before the promised provider consultation, and obstructed cancellation; allegations unproven.
What is on Henry Meds’s record
2025-04
Eli Lilly sued Adonis Health, Inc. d/b/a Henry Meds in the Northern District of California on 23 April 2025 (No. 4:25-cv-03536) over its marketing of compounded tirzepatide against Mounjaro and Zepbound. In September 2025 the court dismissed Lilly's safety and efficacy claims and allowed its personalisation claims to proceed.
Go direct
Both companies, and what we earn from each
We do not recommend one over the other. Where a link pays us, it says so here and on the provider’s own page.
Hims
FDA-approved medication only, from $149 a month. 4 actions on record, each linked on its page. The link below earns us nothing.
Henry Meds
Compounded only, from $179 a month. 1 action on record, each linked on its page. The link below earns us nothing.
Straight answers
Hims vs Henry Meds, in short
- Is Hims or Henry Meds cheaper?
- Hims advertises the lower starting price — $149 a month against $179. Whether that is the cheaper purchase depends on what each figure covers: Hims bills medication separately, and Henry Meds includes it.
- What is the difference between Hims and Henry Meds?
- The one that matters: Henry Meds supplies compounded medication — prepared by a compounding pharmacy, not an FDA-approved product — while Hims supplies FDA-approved drugs only. That is a difference in what arrives, not only in what it costs.
- Which one has more regulatory actions on record?
- Hims, with 4 sourced actions against 1 action for Henry Meds. Every one is linked to its primary document on the provider's own page. A larger file is not automatically a worse company — read what the documents actually say.
Other comparisons: Hims vs Ro (Ro Body) · Hims vs Hers · Hims vs Noom (Noom Med) · Hims vs Calibrate · Hims vs LillyDirect · NovoCare Pharmacy vs Hims